Pilar Varela
Overview
Explore the profile of Pilar Varela including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chaparro M, Hermida S, Acosta D, Fernandez-Clotet A, Barreiro-de Acosta M, Hernandez Martinez A, et al.
Aliment Pharmacol Ther
. 2024 Sep;
60(10):1325-1338.
PMID: 39287363
Background: Ustekinumab is approved for ulcerative colitis (UC). Aims: To assess the durability of ustekinumab in patients with UC and its short-term effectiveness, durability and tolerability in clinical practice. Methods:...
2.
Aguas M, Del Hoyo J, Vicente R, Barreiro-de Acosta M, Melcarne L, Hernandez-Camba A, et al.
J Med Internet Res
. 2024 Aug;
26:e60966.
PMID: 39189160
Background: Telemonitoring for inflammatory bowel disease (IBD) has not consistently demonstrated superiority over standard care; however, noninferiority may be an acceptable outcome if remote care proves to be more efficient....
3.
Gonzalez-Munoza C, Calafat M, Gisbert J, Iglesias E, Minguez M, Sicilia B, et al.
Postgrad Med J
. 2024 Jun;
100(1189):836-844.
PMID: 38913019
Background And Aims: Familial inflammatory bowel disease (IBD) history is a controversial prognostic factor in IBD. We aimed to evaluate the impact of a familial history of IBD on the...
4.
Sanz Segura P, Gomollon F, Casas D, Iborra M, Vela M, Fernandez-Clotet A, et al.
Dig Liver Dis
. 2024 Jun;
56(12):2060-2068.
PMID: 38876834
Background: some patients with inflammatory bowel disease (IBD) treated with antiTNF develop drug-induced psoriasis (antiTNF-IP). Several therapeutic strategies are possible. Aims: to assess the management of antiTNF-IP in IBD, and...
5.
Casanova M, Nantes O, Varela P, Vela-Gonzalez M, Rivero M, Sierra-Gabarda O, et al.
Aliment Pharmacol Ther
. 2023 Apr;
58(1):60-70.
PMID: 37089065
Background And Aims: Data on the outcomes after switching from adalimumab (ADA) originator to ADA biosimilar are limited. The aim was to compare the treatment persistence, clinical efficacy, and safety...
6.
Guerra I, Bujanda L, Manosa M, Perez-Martinez I, Casanova M, de la Pena L, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765708
An increased risk of lymphoma has been described in patients with inflammatory bowel disease (IBD). The aims of our study were to determine the clinical presentation, the previous exposure to...
7.
Chaparro M, Acosta D, Rodriguez C, Mesonero F, Vicuna M, Barreiro-de Acosta M, et al.
Am J Gastroenterol
. 2023 Jan;
118(7):1237-1247.
PMID: 36716287
Introduction: The objective of this study was to assess the durability, short-term and long-term effectiveness, and safety of tofacitinib in ulcerative colitis (UC) in clinical practice. Methods: This is a...
8.
Zabana Y, Marin-Jimenez I, Rodriguez-Lago I, Vera I, Martin-Arranz M, Guerra I, et al.
J Clin Med
. 2022 Dec;
11(24).
PMID: 36556155
(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to...
9.
Barreiro-de Acosta M, Fernandez-Clotet A, Mesonero F, Garcia-Alonso F, Casanova M, Fernandez-De La Varga M, et al.
Am J Gastroenterol
. 2022 Dec;
118(6):1036-1046.
PMID: 36516073
Introduction: The prevalence of penetrating complications in Crohn's disease (CD) increases progressively over time, but evidence on the medical treatment in this setting is limited. The aim of this study...
10.
Chaparro M, Baston-Rey I, Fernandez Salgado E, Gonzalez Garcia J, Ramos L, Palomares M, et al.
J Clin Med
. 2022 Aug;
11(15).
PMID: 35956133
Ustekinumab has shown efficacy in Crohn's Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the...